Apollo Endosurgery Inc. (NASDAQ: (APEN) stock surged by 1.01% at last close while the APEN stock rises by 4.22% in the after-hours trading session. Apollo Endosurgery is a medical technology firm dedicated to the making of next-generation, minimally invasive technologies for therapeutic endoscopy to cure a range of gastrointestinal disorders.

APEN stock’ Significant Update

The Multi-Center ESG Randomized Interventional Trial (MERIT) investigators provided encouraging results, according to Apollo Endosurgery.

The data was given at the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) at the “Top 10 Papers at IFSO” session by Dr. Barham Abu Dayyeh. He is a Professor of Medicine and Director of Advanced Endoscopy at the Mayo Clinic.

• The ESG Procedure Provides Significant and Long-Term Weight Loss, as well as Improvements in Obesity-Related Health Conditions, according to Trial Results.
• The MERIT-Trial accomplished its major safety and effectiveness goals, with patients receiving the Endoscopic Sleeve Gastroplasty (ESG) operation losing 49.2 percent of their extra body weight at 12 months and experiencing just 2% significant side events.
• At 12 months, patients who had ESG exhibited clinically significant decreases in diabetes, hypertension, and metabolic syndrome.

Dr. Abu Dayyeh commented,

The MERIT findings are persuasive, and the medical profession is keen to adopt novel therapeutic options to combat the worldwide obesity epidemic. Endoscopic Sleeve Gastroplasty is a scalable, safe, and successful organ-sparing procedure that may be done by either a gastroenterologist or a bariatric surgeon in an outpatient setting. Furthermore, the ESG treatment can be paired with other therapy alternatives to improve patient results even further.

President and Chief Executive Officer, Chas McKhann, stated,

This is a big step forward in Apollo’s objective to significantly reduce severe obesity and obesity-related health issues, which remain to be a global problem. The MERIT findings corroborate the ESG treatment’s value promise of clinically substantial weight loss via safe, easy outpatient surgery. Following their recent De Novo 510(k) application, they look forward to continuing their efforts with the FDA to get regulatory approval to acknowledge ESG as a viable therapeutic option for patients suffering from obesity.